【Objective】To study the clinical manifestation of EUGOGO（the European Groupon Graves‘ Orbitopathy）classification in Graves’Orbitopathy（GO） .【Methods】In this retrospective study，the clinical charts of GO patients at SunYat-sen Memorial Hospital between January 2010 and December 2016 were reviewed. 【Results】Data were collected from 211 eyes of 110cases. The meanage of all the cases was 47.4（S=12.8）years，27 cases are smoking. Duration of thyroid disease and GO were24.7（S=42.5）months and 10.4（S=23.1）months，respectively. The mean exophthalmic value of cases was 19.1（S=3.1）mm. In EUGOGO classification， they were distributed at all scopeofseverities from grade mild（25cases，22.7%），moderate-severe（56cases，50.9%）to sight-threatening（29cases，26.4%）. Clinically significantactive disease，defined as CAS（Clinical ActivityScore）≥3 was present in 47（42.7%）patients，while others 63 （57.3%）presented in active with CAS<3. In NOSPECS system ，the distribution is mainly concentrated at phase 4（69 cases，62.7%）and phase6（24 cases，21.8%）.In this study，74 cases（67.3%）treated with different regimens of systemic glucocorticoid，15 cases（13.6%）treated with orbital radio therapy and 4cases（3.6%）treated with surgeries（3 cases with orbital decompression and 1 case with strabismus surgery） .【Conclusions】Although the majority of patients in the study were inactive with CAS＜3，more than half of patients presented relatively high severity as moderate-severeor sight-threatening disease. At present，the therapy according to EUGOGO guidelines is rarely used in China and the management of GO are not uniformin clinical practice. Therefore，it is necessary to explore the evidence-based therapeutic methods suitable for Chinese in the future.